title: Pharmacotherapy observed in a large prospective longitudinal study on anxiety disorders.
abstract: Data concerning 331 subjects participating in a longitudinal study on anxiety disorders were collected over the first 6 months of the study. Preliminary analyses of somatic treatment according to diagnoses and study site were conducted. The comorbidity of one anxiety disorder with other DSM-III-R diagnoses and other types of anxiety disorders was extensive. Patients with panic disorder received significantly more treatment with a benzodiazepine than patients without panic disorder. Fewer than five percent of the sample were treated with a monoamine oxidase inhibitor. Comorbid depression increased the likelihood of treatment with a newer non-MAOI (non-monoamine oxidase inhibitor), nontricyclic antidepressant. Results suggest a strong effect of treatment site on the pharmacotherapy offered.
authors.affiliation: Harvard Medical School, Boston, MA.
authors.forename: K A
authors.initials: KA
authors.lastname: Yonkers
authors.forename: J M
authors.initials: JM
authors.lastname: Ellison
authors.forename: D M
authors.initials: DM
authors.lastname: Shera
authors.forename: L A
authors.initials: LA
authors.lastname: Pratt
authors.forename: L M
authors.initials: LM
authors.lastname: Langford
authors.forename: J O
authors.initials: JO
authors.lastname: Cole
authors.forename: K
authors.initials: K
authors.lastname: White
authors.forename: P W
authors.initials: PW
authors.lastname: Lavori
authors.forename: M B
authors.initials: MB
authors.lastname: Keller
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales